Welcome to our dedicated page for SAB BIOTHERAPEUTICS SEC filings (Ticker: SABSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SAB Biotherapeutics, Inc. (SAB BIO), associated in the market with warrants trading under the symbol SABSW, files a range of documents with the U.S. Securities and Exchange Commission that are important for understanding its capital structure, governance, and clinical development funding. These SEC filings relate to the underlying SAB Biotherapeutics common stock and preferred securities that the SABSW warrants reference.
Among the key filings are current reports on Form 8-K, which SAB BIO uses to disclose material events. For example, a Form 8-K dated July 21, 2025 describes a securities purchase agreement for a private placement of Series B Convertible Preferred Stock and related warrants. The filing explains the terms of the preferred stock, its conversion into common stock upon stockholder approval, associated warrants, and the company’s stated intention to use the net proceeds to fully fund the Phase 2b SAFEGUARD study of SAB-142 in Stage 3 type 1 diabetes and for working capital and general corporate purposes. It also summarizes voting rights, dividend provisions, and liquidation preferences for the Series B Preferred Stock.
SAB BIO also files proxy statements on Schedule 14A that detail matters submitted to stockholders. A definitive proxy statement dated August 29, 2025 outlines a special meeting to approve the potential issuance of common stock upon conversion of the Series B Preferred Stock and to amend the 2021 Omnibus Equity Incentive Plan to increase the number of shares available under the plan and adjust the annual evergreen feature. These disclosures provide insight into potential dilution, equity compensation, and changes in control considerations under Nasdaq listing rules.
On this SEC filings page, users can review such documents alongside other periodic and transactional filings as they become available. Filings can help warrant holders and equity investors analyze how preferred stock, warrants, and equity incentive plans may affect the company’s share count and governance. Stock Titan’s tools can pair these filings with AI-powered summaries that highlight key terms, conversion mechanics, voting rights, and use-of-proceeds language, allowing readers to quickly understand how each filing relates to SAB BIO’s clinical strategy for SAB-142 and to the SABSW-linked capital structure.
SAB Biotherapeutics, Inc. entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for clinical and commercial production of its SAB-142 product at Emergent’s Canadian facility. The agreement becomes a long-term framework once SAB-142 receives U.S. FDA approval.
After any FDA approval, the agreement runs for five years and includes a minimum aggregate spend of $36 million over that post-approval term. Emergent has the exclusive right to manufacture SAB-142 during the term, while SAB Biotherapeutics may use alternative sources only when Emergent cannot or declines to supply.
The agreement includes multiple termination rights, including for insolvency, non-payment, material breach, mutual agreement, or extended force majeure. If Emergent terminates due to SAB Biotherapeutics’ insolvency, non-payment, or material breach, SAB Biotherapeutics must pay Emergent an amount equal to the minimum annual aggregate spend for each remaining calendar year, less saved costs.
SAB Biotherapeutics, Inc. entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for clinical and commercial production of its SAB-142 product at Emergent’s Canadian facility. The agreement becomes a long-term framework once SAB-142 receives U.S. FDA approval.
After any FDA approval, the agreement runs for five years and includes a minimum aggregate spend of $36 million over that post-approval term. Emergent has the exclusive right to manufacture SAB-142 during the term, while SAB Biotherapeutics may use alternative sources only when Emergent cannot or declines to supply.
The agreement includes multiple termination rights, including for insolvency, non-payment, material breach, mutual agreement, or extended force majeure. If Emergent terminates due to SAB Biotherapeutics’ insolvency, non-payment, or material breach, SAB Biotherapeutics must pay Emergent an amount equal to the minimum annual aggregate spend for each remaining calendar year, less saved costs.
SAB Biotherapeutics (SABS) reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclose shared beneficial ownership of 3,432,153 shares of Common Stock, representing 5.1% of the class. The filing is a joint Schedule 13G statement dated April 30, 2026.
The percent of the class was calculated using 66,934,576 shares outstanding as of March 17, 2026 per the issuer's prospectus supplement. The reported shares are held through entities over which the reporting persons have shared voting and dispositive power, and a Joint Filing Agreement is attached.
SAB Biotherapeutics (SABS) reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclose shared beneficial ownership of 3,432,153 shares of Common Stock, representing 5.1% of the class. The filing is a joint Schedule 13G statement dated April 30, 2026.
The percent of the class was calculated using 66,934,576 shares outstanding as of March 17, 2026 per the issuer's prospectus supplement. The reported shares are held through entities over which the reporting persons have shared voting and dispositive power, and a Joint Filing Agreement is attached.
SAB Biotherapeutics is holding its 2026 virtual annual stockholder meeting on June 18, 2026 at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/SABS2026. Stockholders will vote on electing four Class II directors for three-year terms and ratifying EisnerAmper LLP as independent auditor for 2026.
Holders of 50,951,037 shares of common stock of record on April 20, 2026 may vote online, by phone, mail or during the virtual meeting. The board describes its governance structure, committee membership, director independence, director compensation and major stockholders, and recommends voting “FOR” all director nominees and “FOR” auditor ratification.
SAB Biotherapeutics is holding its 2026 virtual annual stockholder meeting on June 18, 2026 at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/SABS2026. Stockholders will vote on electing four Class II directors for three-year terms and ratifying EisnerAmper LLP as independent auditor for 2026.
Holders of 50,951,037 shares of common stock of record on April 20, 2026 may vote online, by phone, mail or during the virtual meeting. The board describes its governance structure, committee membership, director independence, director compensation and major stockholders, and recommends voting “FOR” all director nominees and “FOR” auditor ratification.
SAB Biotherapeutics reported new Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established type 1 diabetes. In the six-person cohort, four participants received SAB-142 and two received placebo.
All four treated participants preserved C-peptide, with three classified as super responders showing increases above baseline through Day 120, while the placebo patient showed a decline consistent with disease progression. Treated participants’ continuous glucose monitoring time in range improved from 73% at baseline to 85% at Day 120 without higher exogenous insulin use.
Biomarker data indicated CD4+ T conventional cell exhaustion without immunodepletion, supporting SAB-142’s intended mechanism. A registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes is ongoing, with topline data expected in the second half of 2027.
SAB Biotherapeutics reported new Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established type 1 diabetes. In the six-person cohort, four participants received SAB-142 and two received placebo.
All four treated participants preserved C-peptide, with three classified as super responders showing increases above baseline through Day 120, while the placebo patient showed a decline consistent with disease progression. Treated participants’ continuous glucose monitoring time in range improved from 73% at baseline to 85% at Day 120 without higher exogenous insulin use.
Biomarker data indicated CD4+ T conventional cell exhaustion without immunodepletion, supporting SAB-142’s intended mechanism. A registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes is ongoing, with topline data expected in the second half of 2027.
SAB Biotherapeutics, Inc. chief medical officer Alexandra Kropotova reported a routine tax-related share withholding. On the vesting of restricted stock units, 988 shares of common stock were withheld to satisfy tax obligations, rather than sold in the market. After this disposition, she holds 43,296 shares directly, including 8,743 unvested RSUs, each representing a right to receive one share of common stock.
SAB Biotherapeutics, Inc. chief medical officer Alexandra Kropotova reported a routine tax-related share withholding. On the vesting of restricted stock units, 988 shares of common stock were withheld to satisfy tax obligations, rather than sold in the market. After this disposition, she holds 43,296 shares directly, including 8,743 unvested RSUs, each representing a right to receive one share of common stock.
RA Capital Management and affiliates report beneficial ownership of 7,311,225 shares of SAB Biotherapeutics common stock, representing 9.9% of the class. The position includes common shares, Series B preferred stock, preferred stock warrants and pre-funded warrants, all subject to ownership limits.
On March 19, 2026, the RA Capital Healthcare Fund purchased pre-funded warrants to acquire 2,753,246 common shares at $3.8499 per warrant share, for an aggregate purchase price of $10,599,721.78 funded from its working capital. These pre-funded warrants are immediately exercisable at $0.0001 per share and do not expire, but contain a 9.99% beneficial ownership blocker.
RA Capital Management and affiliates report beneficial ownership of 7,311,225 shares of SAB Biotherapeutics common stock, representing 9.9% of the class. The position includes common shares, Series B preferred stock, preferred stock warrants and pre-funded warrants, all subject to ownership limits.
On March 19, 2026, the RA Capital Healthcare Fund purchased pre-funded warrants to acquire 2,753,246 common shares at $3.8499 per warrant share, for an aggregate purchase price of $10,599,721.78 funded from its working capital. These pre-funded warrants are immediately exercisable at $0.0001 per share and do not expire, but contain a 9.99% beneficial ownership blocker.
SAB Biotherapeutics is offering shares of common stock and pre-funded warrants in a shelf-based public offering. The prospectus supplement describes an offering of common stock and, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share. The company’s common stock trades on The Nasdaq Capital Market under the symbol SABS, and it reported 47,609,899 shares outstanding as of December 31, 2025. The prospectus references proceeds, underwriting arrangements, a 30-day option for additional shares, and customary underwriting terms; specific offering amounts and pricing are presented only in completed prospectus pages. The supplement also summarizes business and clinical developments: SAB-142 is the lead clinical candidate, the company received an IND clearance in May 2024, announced positive Phase 1 topline data across multiple dates including additional Phase 1 data on March 10, 2026, and is advancing SAB-142 into a Phase 2b SAFEGUARD study after a Type B meeting with the FDA on May 29, 2025.
SAB Biotherapeutics is offering shares of common stock and pre-funded warrants in a shelf-based public offering. The prospectus supplement describes an offering of common stock and, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share. The company’s common stock trades on The Nasdaq Capital Market under the symbol SABS, and it reported 47,609,899 shares outstanding as of December 31, 2025. The prospectus references proceeds, underwriting arrangements, a 30-day option for additional shares, and customary underwriting terms; specific offering amounts and pricing are presented only in completed prospectus pages. The supplement also summarizes business and clinical developments: SAB-142 is the lead clinical candidate, the company received an IND clearance in May 2024, announced positive Phase 1 topline data across multiple dates including additional Phase 1 data on March 10, 2026, and is advancing SAB-142 into a Phase 2b SAFEGUARD study after a Type B meeting with the FDA on May 29, 2025.
SAB Biotherapeutics (SAB BIO) reported additional Phase 1 data for its lead Type 1 diabetes therapy SAB-142. In a small cohort of six adults with established Stage 3 T1D, four participants receiving SAB-142 at 2.5 mg/kg showed preserved or increased C-peptide levels at Day 120, while the single placebo completer showed a decline consistent with expected disease progression.
The company highlights biomarker evidence of T‑cell exhaustion supporting the drug’s intended mechanism and notes a previously established Phase 1 safety profile without serum sickness and with transient, reversible lymphopenia. These results supported advancing SAB-142 into the global registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D patients, with topline data planned for the second half of 2027.
SAB Biotherapeutics (SAB BIO) reported additional Phase 1 data for its lead Type 1 diabetes therapy SAB-142. In a small cohort of six adults with established Stage 3 T1D, four participants receiving SAB-142 at 2.5 mg/kg showed preserved or increased C-peptide levels at Day 120, while the single placebo completer showed a decline consistent with expected disease progression.
The company highlights biomarker evidence of T‑cell exhaustion supporting the drug’s intended mechanism and notes a previously established Phase 1 safety profile without serum sickness and with transient, reversible lymphopenia. These results supported advancing SAB-142 into the global registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D patients, with topline data planned for the second half of 2027.
SAB Biotherapeutics is a clinical-stage company developing fully human, multi-specific immunoglobulin therapies, led by SAB-142 for autoimmune type 1 diabetes. SAB-142 advanced from positive Phase 1 results into a registrational Phase 2b SAFEGUARD trial in adults, adolescents and children with new-onset Stage 3 T1D.
For 2025, revenue fell to $0 from $1.3 million in 2024 following termination of a government contract, while research and development expenses rose to $34.4 million and general and administrative expenses increased to $14.6 million as the company expanded clinical and platform work.
SAB reported net income of $13.3 million in 2025 versus a $34.1 million net loss in 2024, driven mainly by a $62.8 million non-cash gain from changes in fair value of warrant liabilities and a $61.0 million total non-operating income line.
Liquidity strengthened significantly: cash, cash equivalents and investments reached $143.5 million at year-end 2025, supported by approximately $175 million of gross proceeds from a Series B preferred stock and warrant offering, and a new Form S-3 shelf for up to $300 million, including a $75 million at-the-market program with UBS.
SAB Biotherapeutics is a clinical-stage company developing fully human, multi-specific immunoglobulin therapies, led by SAB-142 for autoimmune type 1 diabetes. SAB-142 advanced from positive Phase 1 results into a registrational Phase 2b SAFEGUARD trial in adults, adolescents and children with new-onset Stage 3 T1D.
For 2025, revenue fell to $0 from $1.3 million in 2024 following termination of a government contract, while research and development expenses rose to $34.4 million and general and administrative expenses increased to $14.6 million as the company expanded clinical and platform work.
SAB reported net income of $13.3 million in 2025 versus a $34.1 million net loss in 2024, driven mainly by a $62.8 million non-cash gain from changes in fair value of warrant liabilities and a $61.0 million total non-operating income line.
Liquidity strengthened significantly: cash, cash equivalents and investments reached $143.5 million at year-end 2025, supported by approximately $175 million of gross proceeds from a Series B preferred stock and warrant offering, and a new Form S-3 shelf for up to $300 million, including a $75 million at-the-market program with UBS.
Biotechnology Value Fund–affiliated investors reported a significant ownership position in SAB Biotherapeutics, Inc. As of the close of business on December 31, 2025, their funds and a managed account held 30,000 Tranche C warrants for Series A-3 Preferred Stock, convertible into 4,761,906 common shares.
The preferred shares convert at $6.30 per common share, based on a $1,000 per preferred share value, and the warrants are exercisable beginning November 23, 2023 for five years. Using 47,606,851 common shares outstanding as of November 10, 2025, the filing states BVF-related entities may be deemed to beneficially own up to approximately 9.1% of the class.
The structure includes a 9.99% “Maximum Percentage” cap that limits conversions so no holder, together with its affiliates and attribution parties, crosses that ownership threshold.
Biotechnology Value Fund–affiliated investors reported a significant ownership position in SAB Biotherapeutics, Inc. As of the close of business on December 31, 2025, their funds and a managed account held 30,000 Tranche C warrants for Series A-3 Preferred Stock, convertible into 4,761,906 common shares.
The preferred shares convert at $6.30 per common share, based on a $1,000 per preferred share value, and the warrants are exercisable beginning November 23, 2023 for five years. Using 47,606,851 common shares outstanding as of November 10, 2025, the filing states BVF-related entities may be deemed to beneficially own up to approximately 9.1% of the class.
The structure includes a 9.99% “Maximum Percentage” cap that limits conversions so no holder, together with its affiliates and attribution parties, crosses that ownership threshold.